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Abstract
Drug resistant malaria was a major factor contributing to the failure of a worldwide campaign to
eradicate malaria in the last century, and now threatens the large investment being made by the
global community in the rollout of effective new drug combinations to replace failed drugs. Four
related papers in this issue of Malaria Journal make the case for creating the World Antimalarial
Resistance Network (WARN), which will consist of four linked open-access global databases
containing clinical, in vitro, molecular and pharmacological data, and networks of reference
laboratories that will support these databases and related surveillance activities. WARN will serve
as a public resource to guide antimalarial drug treatment and prevention policies and to help
confirm and characterize the new emergence of new resistance to antimalarial drugs and to contain
its spread.
Background
In the mid-20th century, highly effective treatment and
prophylaxis for Plasmodium falciparum malaria with a sin-
gle safe and inexpensive drug, chloroquine, was available
worldwide. For more than a decade, no resistance to chlo-
roquine was seen, leading to optimism that none would
arise, and chloroquine and DDT formed the pillars of a
worldwide campaign to eradicate malaria [1]. After it did
emerge in Southeast Asia and South America, resistance to
chloroquine spread globally, contributing to the aban-
donment of the eradication effort and leading to large
increases in malaria morbidity and mortality [2]. Resist-
ance to the next generations of drugs, first sulphadoxine-
pyrimethamine (SP) and then mefloquine, quickly fol-
lowed their introduction and severely compromised their
efficacy [3-5]. Long after drug resistant malaria has
become a public health crisis in much of the developing
world, passionate advocacy for replacing ineffective mon-
otherapies with new combination therapies designed to
deter resistance is finally being heard and acted upon
[6,7]. Artemisinin-based combination therapies (ACTs)
combine short-acting, highly efficacious artemisinin
derivatives with longer acting partner drugs in an
approach similar to that used to combat drug resistant
tuberculosis and HIV.
Decisions to change malaria treatment policies are usually
made at a national level without consideration of local
differences in drug efficacy and without serious efforts to
coordinate strategies for deterring resistance on a regional
or global level [8]. With a few notable exceptions, the
results of this uncoordinated approach have been subop-
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been made based on insufficient evidence, and treatment
policy changes have been made too late and implemented
too ineffectively, at a huge cost to health and life in addi-
tion to the heavy financial burden to households and
healthcare providers.
The high levels of support and enthusiasm accompanying
the roll-out of ACTs create an historic opportunity to get it
right this time. The transition from 20th century mono-
therapies to 21st century ACTs has spurred a massive
increase in the number of studies of clinical drug efficacy
being conducted, many accompanied by the research on
genetic correlates of drug resistant malaria and the
changes of in vitro responses of P. falciparum to antimalar-
ial drugs. Moreover, the relationship between the pharma-
cokinetics and treatment response is being elucidated for
key antimalarials The World Health Organization has
recently published a compendium of these data [9] and a
number of meta-analyses have been published [10-13].
However, the many differences among the studies in
design, execution and analysis, and especially in formats
for recording and reporting data, reduce greatly the utility
of these pooled datasets [14,15]. In addition, access is fre-
quently limited to the summary data, and data from
unpublished studies is often not available. Thus, a new
approach to collation, analysis and presentation of the
data on drug resistant malaria is urgently needed.
More than 50 countries have changed their national pol-
icy to recommend ACTs as the first line treatment for fal-
ciparum malaria, but in many malaria endemic countries
both financial and practical difficulties have slowed the
implementation of these new policies. There is vigorous
debate about which drug combinations are the most suit-
able and how these new treatments should be deployed
and funded. In this context, it is of paramount importance
to policymakers, funding bodies and researchers, to docu-
ment the clinical efficacy of existing treatments and estab-
lish an ongoing surveillance system to monitor the
continued efficacy of new antimalarials. Moreover, there
is little doubt that resistance will eventually evolve, even
to the ACTs. When this happens, the earliest possible
warning of resistance to either the artemisinin derivatives
or their partner drugs will be the key to avoiding the dis-
aster that would entail the loss of this pivotal class of
drugs. It is even possible that a sensitive global surveil-
lance system for ACT resistance could guide strategies to
contain and deter resistance.
The plan
Four papers in this issue propose the creation of a web-
based World Antimalarial Resistance network (WARN)
that would be accessible to all users. This comprehensive
efficacy and resistance database will provide malaria con-
trol managers, surveillance programs and policymakers
with prompt access to up-to-date evidence of temporal
and geographic trends in antimalarial drug resistance at
the global scale. By detecting early indications of resist-
ance, the database will permit focused epidemiological
and parasitological investigations to confirm, or impor-
tantly, refute, suspected antimalarials drug resistance, pro-
viding evidence to support the case for or against a change
in treatment policy. In addition, it would inform optimal
utilization of antimalarials and facilitate the longest pos-
sible useful therapeutic life of the available antimalarial
drugs and drug combinations.
These goals require a robust, prompt, accessible, flexible
and comprehensive collation of high quality data on anti-
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List of papers in this issue describing creation of global clinical, in vitro, molecular and clinical pharmacology databases compris-
ing a World Antimalarial Resistance Network (WARN).
World Antimalarial Resistance Network (WARN) I: Clinical efficacy of antimalarial therapy 
Provides a rationale and plan for developing a comprehensive open-access database containing individual patient data from clinical trials of 
antimalarial drugs to identify global trends in therapeutic efficacy 
World Antimalarial Resistance Network (WARN) II: In vitro antimalarial drug susceptibility 
Describes the creation of a global network of laboratories for in vitro monitoring of antimalarial drug susceptibility and highlights the critical role of in 
vitro surveillance to detect emergence of resistance to artemisinins and ACT partner drugs 
World Antimalarial Resistance Network (WARN) III: Molecular markers for drug resistant malaria 
Provides a rationale and plan for developing a global database for molecular resistance markers to help guide choices of first-line drugs and to 
accelerate the identification and validation of new markers of resistance to artemisinins and ACT partner drugs 
World Antimalarial Resistance Network (WARN) IV: Clinical pharmacology 
Describes the need for a network of reference laboratories and pooled pharmacokinetic-pharmacodynamic data to distinguish whether treatment 
failure is due to inadequate drug levels or to intrinsic parasite resistance Page 2 of 3
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malarial drugs therapeutic efficacy, molecular and in vitro
markers of resistance, and the relationship between drug
dose, concentration and treatment response.
The proposed database will be modular and incorporate
data of four different kinds: clinical drug efficacy, defini-
tion and prevalence of molecular markers of resistance to
particular drugs, in vitro response of reference and clinical
isolates to drugs under study, and the pharmacokinetic
and pharmacodynamic properties of these drugs in
important target populations. It will include tools that
facilitate keying and entering the data into the database,
and tools that will enable sophisticated analysis and out-
put of the data in formats useful to a wide variety of users.
These tools will be freely available to all in the commu-
nity, and should facilitate the preparation of data for pub-
lication. The goal is to provide a timely and efficient locus
for all groups involved in the determination of drug
responses to P. falciparum to access and share data that are
relevant to this important issue. The creation and mainte-
nance of the database will provide significant opportuni-
ties for development of local capacity for use of tools of
analysis and presentation of data collected in a wide vari-
ety of settings.
The four papers that follow (Figure 1) make the case for a
WARN organized by the four types of data it would incor-
porate: clinical, molecular, in vitro and pharmacokinetic;
and propose a framework for establishment and use of
information in each module and for the linkage of the
information between modules.
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